Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Allyson Zella Prater

Physician Assistant, Medical Pittsburgh, PA Physician Assistant

NPI 1265490742 CMS profile 10731754

665 Rodi Rd Ste 103, Pittsburgh, PA 15235

Open in the dashboard

General payments

$31,735

1,718 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allyson Zella Prater of Pittsburgh, PA is reported in the CMS Open Payments database as having received $31,735 across 1,718 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,031 326
2024 General $6,526 350
2023 General $5,752 304
2022 General $5,877 373
2021 General $6,548 365

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allyson Zella Prater
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Allyson Zella Prater were reported at $7,031. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Allyson Zella Prater Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $6,548 $156 $41–$563 $132
2022 $5,877 $185 $55–$649 $149
2023 $5,752 $199 $58–$717 $160
2024 $6,526 $206 $62–$740 $164
2025 $7,031 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,444 199 payments
  2. Novartis Pharmaceuticals Corporation $1,855 119 payments
  3. Teva Pharmaceuticals USA, Inc. $1,793 105 payments
  4. Biogen, Inc. $1,686 84 payments
  5. Lundbeck LLC $1,362 82 payments
  6. Eisai Inc. $1,354 60 payments
  7. Alexion Pharmaceuticals, Inc. $1,297 32 payments
  8. EMD Serono, Inc. $1,292 62 payments
  9. Genzyme Corporation $1,282 30 payments
  10. ACADIA Pharmaceuticals Inc $1,120 65 payments
  11. Other $15,250 880 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $29,403 1,686 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $981 17 payments
  3. Consulting Fee $475 3 payments
  4. Travel and Lodging $469 1 payment
  5. Education $257 10 payments
  6. Honoraria $150 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $2,106 103 payments
  2. UBRELVY $2,033 134 payments
  3. Leqembi $1,276 56 payments
  4. KESIMPTA $1,126 66 payments
  5. NURTEC ODT $994 95 payments
  6. ZEPOSIA $993 67 payments
  7. TYSABRI $962 35 payments
  8. NUPLAZID $947 49 payments
  9. VYEPTI $921 58 payments
  10. AUBAGIO $917 26 payments
  11. Other $20,751 1,161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

3,510

Median for Physician Assistant: 241

Drug cost

$1,955,731

Median for Physician Assistant: $4,110

Branded share of claims

34.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 24 $346,348
Kesimpta Pen Ofatumumab Brand 26 $244,017
Aubagio Teriflunomide Brand 21 $186,950
Mayzent Siponimod Brand 11 $144,567
Rebif Rebidose Interferon Beta-1a/Albumin Brand 13 $134,518
Nurtec Odt Rimegepant Sulfate Brand 102 $132,867
Avonex Pen (4 Pack) Interferon Beta-1a Brand 12 $94,282
Glatiramer Acetate Generic 52 $91,482
Copaxone Glatiramer Acetate Brand 12 $70,964
Botox Onabotulinumtoxina Brand 45 $59,917

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
$508 — —
QULIPTA
$500 23 —
LUMRYZ
$408 — —
KESIMPTA
$377 26 —
Austedo XR
$343 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

1,718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record